Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Estimation of endogenous anti-oxidant capacity in brain tissue of the experimental groups

From: Systems pharmacology based approach to investigate the in-vivo therapeutic efficacy of Albizia lebbeck (L.) in experimental model of Parkinson’s disease

GroupsTreatmentDOSEGSH (μg/mg of brain tissue)SOD (μg/mg of brain tissue)CAT (μg/mg of brain tissue)
INormal controlN/A80.67 ± 0.86624.193 ± 0.677621.92 ± 0.487
IIDisease control (HPD)1 mg/kg55.624 ± 1.77416.4716 ± 0.6493.0733 ± 0.214
IIIStandard control (STD)100 mg/kg79.944 ± 1.772***22.88 ± 0.407***13.0083 ± 0.722***
IVTreatment control (ALE 100)100 mg./ kg71.29 ± 2.33 ***21.513 ± 0.574**11.612 ± 0.485***
VTreatment control (ALE 200)200 mg/ kg77.984 ± 1.098***22.234 ± 0.627**16.1416 ± 0.593***
VITreatment control (ALE 300)300 mg/kg78.577 ± 1.546***23.197 ± 0.6389***19.55 ± 1.209***
  1. *** P < 0.001 and ** P < 0.01 as compared to disease group. Each value is mean ± SEM